| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis. |
| 掲載誌名 | 正式名：JTO clinical and research reports 略 称：JTO Clin Res Rep ISSNコード：26663643/26663643 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 7(4),pp.100972 |
| 著者・共著者 | Masashi Ishihara, Takahisa Kawamura, Yukiko Namba, Yuki Takeyasu, Yukihiro Hasegawa, Yuki Sato, Yoshiki Negi, Tomohiro Oba, Toshiyuki Sumi, Hirokuni Hirata, Hidemitsu Funabashi, Yuko Oya, Hajime Kikuchi, Motoko Tachihara, Takeshi Nakatani, Taishi Harada, Keiko Tanimura, Taku Nakagawa, Naoya Takeda, Takahiro Asami, Osamu Honjo, Hiromi Nagashima, Takumi Yamaura, Norihiko Hata, Miyako Kitazono, Naoya Nishioka, Akihiro Tamiya, Yuichi Sakamori, Ryota Shigaki, Kyoichi Kaira, Ryoichi Honda, Takashi Matsui, Eriko Suzuki, Kentaro Ito, Kojiro Otsuka, Yuko Yoshizumi, Yusuke Murakami, Kazuhiko Matsuno, Sumito Inoue, Akira Kisohara, Sojiro Kusumoto, Hiroe Aoshima, Yumiko Kakizaki, Akihito Kubo, Akito Hata, Nobuhisa Ishikawa, Kosuke Hamai, Nobuhiro Kanaji, Nobuaki Mamesaya, Toshihiro Misumi, Noriyuki Matsutani, Nobuhiko Seki |
| 発行年月 | 2026/04 |
| 概要 | INTRODUCTION:EGFR tyrosine kinase inhibitors, including osimertinib, generally exhibit lower efficacy in patients with the L858R-mutant NSCLC compared with those with exon 19 deletion (del19). Ramucirumab (RAM) plus erlotinib (ERL), however, has demonstrated comparable efficacy in patients with either del19 or L858R mutations. Despite these findings, the real-world clinical efficacy of the RAM plus ERL combination therapy for the L858R-mutation NSCLC remains unclear, particularly in patients with central nervous system metastases.METHODS:The authors performed a retrospective multicenter cohort study for 168 patients with L858R-mutant NSCLC treated with RAM plus ERL as a first-line treatment between November 2020 and August 2023.RESULTS:The median time to treatment failure was 12.2 months (95% confidence interval [CI]: 9.5-15.5), and the median progression-free survival was 17.4 months (95% CI: 14.8-24.8). The median overall survival was 35.6 months (95% CI: 30.3-not calculable), resulting in 77.8% at a 2-year survival rate. The objective response rate was 75.0%, and the disease control rate was 88.7%. Among the cohort, 43 patients (26%) had central nervous system metastasis, with a median progression-free survival of 15.1 months (95% CI: 8.2-19.9). The most common adverse events were dermatitis acneiform (71%), paronychia (43%), and diarrhea (39%). Grade more than or equal to 3 adverse events occurred in 42% of patients.CONCLUSIONS:In real-world settings, RAM plus ERL demonstrated favorable efficacy in patients with L858R-mutant NSCLC and manageable toxicity. |
| DOI | 10.1016/j.jtocrr.2026.100972 |
| PMID | 41938081 |